

CROHN'S DISEASE/ULCERATIVE COLITIS REFERRAL FORM A-G



Patient Information

Patient Name: _____ DOB: _____ Sex: M F
 Phone: _____ Cell Phone: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 ICD-10 Diagnosis Code: _____ Diagnosis: _____ Weight: _____
 Allergies (please note reaction): _____ Latex
 Current Medications: (list here or attach a medication list): _____
 Comorbidities: (list here or attach a list): _____

INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Cimzia (certolizumab)	<input type="checkbox"/> Starter Kit 200mg/mL Prefilled Syringe	<input type="checkbox"/> Loading Dose: Inject 400mg (2 syringes) subcutaneously at weeks 0, 2 and 4.	1 kit (6 syringes)	
	<input type="checkbox"/> 200mg/mL Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 400mg (2 syringes) subcutaneously every 4 weeks.	2 syringes	
<input type="checkbox"/> Entyvio (vedolizumab)	300mg/20mL vial	<input type="checkbox"/> Loading Dose: Administer 300mg intravenously at 0, 2 and 6 weeks.	3 vials	
		<input type="checkbox"/> Maintenance Dose: Administer 300mg intravenously every 8 weeks.	1 vial	

Treatment History: New to Therapy Continuation of Therapy

Crohn's Severity: Moderate Severe
 Enterocutaneous/Rectovaginal Fistulas? Yes No
 Does patient have serious/active infection? Yes No
 Has tuberculosis been assessed? Yes No
 Date assessed: _____ Results: _____
 Comments: _____
 Is patient at risk for Hepatitis B infection? Yes No
 If Yes, has Hepatitis B been ruled out or treatment initiated? Yes No

Prescriber Information

Prescriber Name: _____
 State License #: _____ DEA #: _____ NPI: _____
 Additional Contact Person Name: _____
 Group or Hospital: _____ Phone: _____
 Fax: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Prescriber Signature: _____
 Product Substitution Permitted _____ Dispensed as Written _____ Date _____

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient Ship to Prescriber/Clinic Pick up at Albertsons Companies Pharmacy Date Medication Needed: _____

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.

CROHN'S DISEASE/ULCERATIVE COLITIS REFERRAL FORM H



Patient Information

Patient Name: _____ DOB: _____ Sex: M F
 Phone: _____ Cell Phone: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 ICD-10 Diagnosis Code: _____ Diagnosis: _____ Weight: _____
 Allergies (please note reaction): _____ Latex
 Current Medications: (list here or attach a medication list): _____
 Comorbidities: (list here or attach a list): _____

INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Humira (adalimumab)	<input type="checkbox"/> Citrate-free Crohn's Starter Kit (3 pens) <input type="checkbox"/> Crohn's Starter Kit (6 pens)	<input type="checkbox"/> Adult Loading Dose: Inject 160mg subcutaneously on day 1, then 80mg on day 15.	1 kit	
	<input type="checkbox"/> Citrate-free Crohn's Pediatric Starter Kit (2 prefilled syringes) <input type="checkbox"/> Crohn's Pediatric Starter Kit (3 prefilled syringes)	<input type="checkbox"/> Pediatric 6 years and older, 17 to < 40 kg Loading Dose: Inject 80mg subcutaneously on day 1, then 40mg on day 15.	1 kit	
	<input type="checkbox"/> Citrate-free Crohn's Pediatric Starter Kit (3 prefilled syringes) <input type="checkbox"/> Crohn's Pediatric Starter Kit (6 prefilled syringes)	<input type="checkbox"/> Pediatric 6 years and older, ≥ 40 kg Loading Dose: Inject 160mg subcutaneously on day 1, then 80mg on day 15.	1 kit	
	<input type="checkbox"/> 40mg/0.4 mL Citrate-free Pen <input type="checkbox"/> 40mg/0.8 mL Pen <input type="checkbox"/> 40mg/0.4 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 40mg/0.8 mL Prefilled Syringe	<input type="checkbox"/> Adult or Pediatric 6 years or older, ≥ 40 kg Maintenance Dose: Inject 40mg subcutaneously on day 29 then every OTHER week thereafter.	2 pens/syringes	
	<input type="checkbox"/> 20mg/0.2 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 20mg/0.4 mL Prefilled Syringe	<input type="checkbox"/> Pediatric 6 years and older, 17 to < 40 kg Maintenance Dose: Inject 20mg subcutaneously on day 29 then every OTHER week thereafter.	2 syringes	

Treatment History: New to Therapy Continuation of Therapy

Crohn's Severity: Moderate Severe
 Enterocutaneous/Rectovaginal Fistulas? Yes No
 Does patient have serious/active infection? Yes No
 Has tuberculosis been assessed? Yes No
 Date assessed: _____ Results: _____
 Comments: _____
 Is patient at risk for Hepatitis B infection? Yes No
 If Yes, has Hepatitis B been ruled out or treatment initiated? Yes No

Prescriber Information

Prescriber Name: _____
 State License #: _____ DEA #: _____ NPI: _____
 Additional Contact Person Name: _____
 Group or Hospital: _____ Phone: _____
 Fax: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____

Prescriber Signature: _____ Product Substitution Permitted _____ Dispensed as Written _____ Date _____

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient Ship to Prescriber/Clinic Pick up at Albertsons Companies Pharmacy Date Medication Needed: _____

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.

CROHN'S DISEASE/ULCERATIVE COLITIS REFERRAL FORM I-T



Patient Information

Patient Name: _____ DOB: _____ Sex: M F
 Phone: _____ Cell Phone: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 ICD-10 Diagnosis Code: _____ Diagnosis: _____ Weight: _____
 Allergies (please note reaction): _____ Latex
 Current Medications: (list here or attach a medication list): _____
 Comorbidities: (list here or attach a list): _____

INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Remicade (infliximab)	100mg Vial	<input type="checkbox"/> Loading Dose: Administer _____mg (at _____mg/kg) intravenously at 0, 2 and 6 weeks.		
<input type="checkbox"/> Inflectra (infliximab-dyyb)		<input type="checkbox"/> Maintenance Dose: Administer _____mg (at _____mg/kg) intravenously every _____weeks.		
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 100mg/mL SmartJect	<input type="checkbox"/> Loading Dose: Inject 200mg (two 100mg injections subcutaneously at week 0, then 100mg at week 2, followed by maintenance dose.	3 syringes/ SmartJect	
	<input type="checkbox"/> 100mg/mL Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 100mg subcutaneously every 4 weeks.	1 syringe/ SmartJect	
<input type="checkbox"/> Stelara (ustekinumab)	90mg/mL Prefilled Syringe	Inject 90mg (one syringe) subcutaneously every 8 weeks.	1 syringe	
<input type="checkbox"/> Tysabri (natalizumab)	300mg/15mL Concentrate	Administer 300mg via intravenous infusion over 1 hour every 4 weeks.	1 vial	

Treatment History: New to Therapy Continuation of Therapy

Crohn's Severity: Moderate Severe
 Enterocutaneous/Rectovaginal Fistulas? Yes No
 Does patient have serious/active infection? Yes No
 Has tuberculosis been assessed? Yes No
 Date assessed: _____ Results: _____
 Comments: _____
 Is patient at risk for Hepatitis B infection? Yes No
 If Yes, has Hepatitis B been ruled out or treatment initiated? Yes No

Prescriber Information

Prescriber Name: _____
 State License #: _____ DEA #: _____ NPI: _____
 Additional Contact Person Name: _____
 Group or Hospital: _____ Phone: _____
 Fax: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____

Prescriber Signature: _____ Product Substitution Permitted _____ Dispensed as Written _____ Date _____

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient Ship to Prescriber/Clinic Pick up at Albertsons Companies Pharmacy Date Medication Needed: _____

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.

CROHN'S DISEASE/ULCERATIVE COLITIS REFERRAL FORM U-Z



Patient Information

Patient Name: _____ DOB: _____ Sex: M F
 Phone: _____ Cell Phone: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 ICD-10 Diagnosis Code: _____ Diagnosis: _____ Weight: _____
 Allergies (please note reaction): _____ Latex
 Current Medications: (list here or attach a medication list): _____
 Comorbidities: (list here or attach a list): _____

INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Xeljanz (tofacitinib)	<input type="checkbox"/> 10mg <input type="checkbox"/> 22mg XR	<input type="checkbox"/> Loading Dose: Take 1 tablet by mouth twice daily for ___ weeks. <input type="checkbox"/> Loading Dose: Take 1 tablet (22mg) by mouth once daily for ___ weeks.		
	<input type="checkbox"/> 5mg <input type="checkbox"/> 10mg <input type="checkbox"/> 11mg XR	<input type="checkbox"/> Maintenance Dose: Take 1 tablet by mouth twice daily. <input type="checkbox"/> Maintenance Dose: Take 1 tablet by mouth once daily. (5mg only) <input type="checkbox"/> Maintenance Dose: Take 1 tablet (11mg) by mouth once daily.	<input type="checkbox"/> 60 tablets <input type="checkbox"/> 30 tablets	
Other Medication Name:				

Treatment History: New to Therapy Continuation of Therapy

Crohn's Severity: Moderate Severe
 Enterocutaneous/Rectovaginal Fistulas? Yes No
 Does patient have serious/active infection? Yes No
 Has tuberculosis been assessed? Yes No
 Date assessed: _____ Results: _____
 Comments: _____
 Is patient at risk for Hepatitis B infection? Yes No
 If Yes, has Hepatitis B been ruled out or treatment initiated? Yes No

Prescriber Information

Prescriber Name: _____
 State License #: _____ DEA #: _____ NPI: _____
 Additional Contact Person Name: _____
 Group or Hospital: _____ Phone: _____
 Fax: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____

Prescriber Signature: _____ Product Substitution Permitted _____ Dispensed as Written _____ Date _____

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient Ship to Prescriber/Clinic Pick up at Albertsons Companies Pharmacy Date Medication Needed: _____

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.